Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01571297 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
A Phase 2 study, sponsored by Motus Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT01571297 is a Phase 2 study that has completed, run by Motus Therapeutics. The registered enrollment target is 204 participants.
The verdict
NCT01571297, a Phase 2 study, has completed, sponsored by Motus Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of RM-131 on gastric emptying, gastroparesis symptoms, and the safety and tolerability of RM-131 compared to placebo in patients with Type 1 and Type 2 diabetes mellitus and gastroparesis. The study is designed to evaluate the efficacy and safety of multiple dose regimens of RM-131. Study drug (RM-131 and placebo) will be administered subcutaneously in a blinded fashion.
Interventions
- DRUG Placebo
- DRUG RM-131
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01571297
The ClinicalTrials.gov registry entry for NCT01571297 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Motus Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01571297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01571297 about?
NCT01571297 is a clinical study titled "Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis". The purpose of this study is to evaluate the effects of RM-131 on gastric emptying, gastroparesis symptoms, and the safety and tolerability of RM-131 compared to placebo in patients with Type 1 and Type 2 diabetes mellitus and gastroparesis. The study is designed to evaluate the efficacy and safety ...
What is the current status of trial NCT01571297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2012-04. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01571297?
The interventions under investigation include: Placebo (DRUG), RM-131 (DRUG).
Who is sponsoring clinical trial NCT01571297?
This trial is sponsored by Motus Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.